CytoTools AG

CytoTools AG, rebranded as bioXXmed AG in 2022, is a German biotechnology holding company that specializes in the development of disease-modifying therapies. The company focuses on leveraging molecular mechanisms of cell growth and programmed cell death (apoptosis) to treat chronic diseases. Its primary investment focus is currently in dermatology, specifically targeting hard-to-heal chronic wounds such as diabetic foot ulcers and venous leg ulcers. The company operates as an active portfolio manager, financing biomedical projects through independent subsidiaries like DermaTools Biotech GmbH and rancoderm GmbH. Its lead product, DermaPro, is a patented small molecule substance (DPOCL) that has demonstrated significant efficacy in clinical trials. bioXXmed AG does not conduct direct R&D but manages the patent portfolios and coordinates licensing and regulatory pathways for its portfolio companies.